Los Angeles Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Los Angeles Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.74M	Buy	15,641 +6,422	+70%	+$581K	0.01%	621
2026 Q1	$802K	Sell	9,219 -15,115	-62%	-$1.47M	﹤0.01%	739
2025 Q4	$2.72M	Buy	24,334 +7,613	+46%	+$808K	0.01%	390
2025 Q3	$1.69M	Buy	16,721 +12,849	+332%	+$1.19M	0.01%	545
2025 Q2	$245K	Buy	+3,872	New	+$237K	﹤0.01%	1120
2024 Q1	–	Sell	-10,593	Closed	-$487K	–	1213
2023 Q4	$487K	Sell	10,593 -2,828	-21%	-$89.2K	﹤0.01%	877
2023 Q3	$308K	Buy	+13,421	New	+$301K	﹤0.01%	953
2021 Q1	–	Sell	-12,129	Closed	-$361K	–	1643
2020 Q4	$361K	Sell	12,129 -250	-2%	-$6.35K	﹤0.01%	1320
2020 Q3	$268K	Buy	+12,379	New	+$284K	﹤0.01%	1301

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Los Angeles Capital Management's RYTM Position: Q2 2026 in Review

Los Angeles Capital Management increased its Rhythm Pharmaceuticals (RYTM) stake by 70% in Q2 2026, buying an estimated $581K and bringing the position to 15,641 shares worth $1.74M. The position accounts for 0.01% of the portfolio, ranked #621.

Los Angeles Capital Management first reported a position in RYTM in Q3 2020 and has held it in 9 quarters since. The position peaked at $2.72M in Q4 2025. 305 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Los Angeles Capital Management held 15,641 shares of Rhythm Pharmaceuticals worth $1.74M as of Q2 2026.
Los Angeles Capital Management bought 6,422 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $581K.
Rhythm Pharmaceuticals made up 0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #621 holding.
Los Angeles Capital Management first reported a position in Rhythm Pharmaceuticals in Q3 2020 and has held it in 9 quarters since.
Los Angeles Capital Management's Rhythm Pharmaceuticals position peaked at $2.72M in Q4 2025.
305 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.